Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
Introduction: Multiple immune checkpoint inhibitors (ICIs) that modulate immune cells in the periphery and the tumor microenvironment (TME) have been approved, as have the therapeutic cancer vaccines sipuleucel-T for metastatic castration-resistant prostate cancer and talimogene laherparepvec (T-VEC...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-08-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14760584.2018.1506332 |